PTGX Stock Summary and Trading Ideas (Protagonist Therapeutics | NASDAQ:PTGX)

Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.

Protagonist Therapeutics trades on the NASDAQ stock market under the symbol PTGX.

As of May 16, 2024, PTGX stock price climbed to $31.94 with 384,390 million shares trading.

PTGX has a beta of 1.62, meaning it tends to be more sensitive to market movements. PTGX has a correlation of 0.19 to the broad based SPY ETF.

PTGX has a market cap of $1.87 billion. This is considered a Small Cap stock.

Last quarter Protagonist Therapeutics reported $255 million in Revenue and $3.26 earnings per share. This beat revenue expectation by $135 million and exceeded earnings estimates by $.75.

In the last 3 years, PTGX stock traded as high as $50.54 and as low as $6.91.

The top ETF exchange traded funds that PTGX belongs to (by Net Assets): XBI, VTI, IWM, VXF, IBB.

PTGX stock has underperformed the market in the last year with a return of +23.0%, while SPY returned +29.6%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in PTGX shares. However, PTGX has outperformed the market in the last 3 month and 2 week periods, returning +13.1% and +25.0%, while SPY returned +5.6% and +5.7%, respectively. This indicates PTGX has been having a stronger performance recently.

PTGX support price is $30.52 and resistance is $32.42 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PTGX stock will trade within this expected range on the day.